Plasma fasting and nonfasting triglycerides and high-density lipoprotein cholesterol in atherosclerotic stroke: Different profiles according to low-density lipoprotein cholesterol

Atherosclerosis

Volumn 223, Issue 2, 2012, Pages 463-467

  Kim, Suk Jae ^a   Park, Yun Gyoung ^a   Kim, Ji Hyun ^a   Han, Yun Kyung ^a   Cho, Hong Keun ^b   Bang, Oh Young ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Dr Cho's Internal Medicine Clinic   (South Korea)

Author keywords

Apolipoprotein A5; Atherosclerotic stroke; Cholesterol; Triglycerides

Indexed keywords

APOLIPOPROTEIN A5; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; HOSPITAL ADMISSION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS A; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FASTING; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; STROKE; TRIGLYCERIDES;

EID: 84864752127     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.05.011     Document Type: Article

References (30)

1. Adams R.J., Albers G., Alberts M.J., et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008, 39(5):1647-1652.
2. Amarenco P., Bogousslavsky J., Callahan A., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006, 355(6):549-559.
3. Furie K.L., Kasner S.E., Adams R.J., et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011, 42(1):227-276.
4. Sacco R.L., Adams R., Albers G., et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006, 37(2):577-617.
5. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298(3):309-316.
6. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298(3):299-308.
7. Varbo A., Nordestgaard B.G., Tybjaerg-Hansen A., Schnohr P., Jensen G.B., Benn M. Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population. Ann Neurol 2011, 69(4):628-634.
8. Shaikh M., Wootton R., Nordestgaard B.G., et al. Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb 1991, 11(3):569-577.
9. Pennacchio L.A., Olivier M., Hubacek J.A., et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001, 294(5540):169-173.
10. Bang O.Y., Saver J.L., Liebeskind D.S., Pineda S., Ovbiagele B. Association of serum lipid indices with large artery atherosclerotic stroke. Neurology 2008, 70(11):841-847.
11. Nah H.W., Kang D.W., Kwon S.U., Kim J.S. Diversity of single small subcortical infarctions according to infarct location and parent artery disease: analysis of indicators for small vessel disease and atherosclerosis. Stroke 2010, 41(12):2822-2827.
12. Ryoo S., Park J.H., Kim S.J., et al. Branch occlusive disease: clinical and magnetic resonance angiography findings. Neurology 2012, 78(12):888-896.
13. Alberti K.G., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the study of obesity. Circulation 2009, 120(16):1640-1645.
14. Kim S.J., Choe Y.H., Park S.J., et al. Routine cardiac evaluation in patients with ischaemic stroke and absence of known atrial fibrillation or coronary heart disease: transthoracic echocardiography vs. multidetector cardiac computed tomography. Eur J Neurol 2011.
15. Ay H., Furie K.L., Singhal A., Smith W.S., Sorensen A.G., Koroshetz W.J. An evidence-based causative classification system for acute ischemic stroke. Ann Neurol 2005, 58(5):688-697.
16. Tirschwell D.L., Smith N.L., Heckbert S.R., Lemaitre R.N., Longstreth W.T., Psaty B.M. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004, 63(10):1868-1875.
17. Ridker P.M., Rifai N., Cook N.R., Bradwin G., Buring J.E. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005, 294(3):326-333.
18. Kim S.J., Song P., Park J.H., et al. Biomarkers of asymptomatic carotid stenosis in patients undergoing coronary artery bypass grafting. Stroke 2011, 42(3):734-739.
19. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360(9346):1623-1630.
20. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383-1389.
21. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364(9435):685-696.
22. Ginsberg H.N. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002, 106(16):2137-2142.
23. Freiberg J.J., Tybjaerg-Hansen A., Jensen J.S., Nordestgaard B.G. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008, 300(18):2142-2152.
24. Schaap F.G., Rensen P.C., Voshol P.J., et al. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 2004, 279(27):27941-27947.
25. Fruchart-Najib J., Bauge E., Niculescu L.S., et al. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun 2004, 319(2):397-404.
26. Pennacchio L.A., Olivier M., Hubacek J.A., Krauss R.M., Rubin E.M., Cohen J.C. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 2002, 11(24):3031-3038.
27. Elosua R., Ordovas J.M., Cupples L.A., et al. Variants at the APOA5 locus, association with carotid atherosclerosis, and modification by obesity: the Framingham Study. J Lipid Res 2006, 47(5):990-996.
28. Havasi V., Szolnoki Z., Talian G., et al. Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglyceride levels and confers susceptibility for development of ischemic stroke. J Mol Neurosci 2006, 29(2):177-183.
29. Talmud P.J., Martin S., Taskinen M.R., et al. APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. J Lipid Res 2004, 45(4):750-756.
30. van der Vleuten G.M., Isaacs A., Zeng W.W., et al. Haplotype analyses of the APOA5 gene in patients with familial combined hyperlipidemia. Biochim Biophys Acta 2007, 1772(1):81-88.